Pegunigalsidase Alfa (Elfabrio) — Coverage Criteria
Customize your policy alerts
Sign up for Health Net Policy CP PHAR.512 alerts
Get alerted when Policy CP PHAR.512 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for Elfabrio (pegunigalsidase alfa-iwxj) for treatment of adults with confirmed Fabry disease for Health Net lines of business including Commercial, HIM, and Medicaid.
Added HCPCS code J2508 to coding.
Added concomitant use exclusion to the Continued Therapy section to mirror the Initial Approval Criteria and added requirement for documentation of member's weight for dose calculation.
References reviewed and updated during annual reviews (3Q 2024 and 2Q 2025) with no significant clinical changes otherwise.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.